The University of Chicago Header Logo

Connection

Theodore Karrison to Male

Back to Details
This is a "connection" page, showing publications Theodore Karrison has written about Male.
Theodore Karrison
Connection Strength
1.016
Male
  1. Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
    View in: PubMed
    Score: 0.047
  2. Effects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area. J Trauma Acute Care Surg. 2018 Oct; 85(4):756-765.
    View in: PubMed
    Score: 0.032
  3. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.029
  4. Estimation of progression-free survival in the randomized discontinuation trial design. J Clin Oncol. 2013 Feb 20; 31(6):814.
    View in: PubMed
    Score: 0.021
  5. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.021
  6. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.
    View in: PubMed
    Score: 0.016
  7. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.012
  8. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
    View in: PubMed
    Score: 0.012
  9. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.
    View in: PubMed
    Score: 0.012
  10. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.012
  11. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
    View in: PubMed
    Score: 0.012
  12. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003 Oct; 99(4):644-52.
    View in: PubMed
    Score: 0.011
  13. The aspect ratio (dome/neck) of ruptured and unruptured aneurysms. J Neurosurg. 2003 Sep; 99(3):447-51.
    View in: PubMed
    Score: 0.011
  14. Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy. J Stroke Cerebrovasc Dis. 2023 Aug; 32(8):107227.
    View in: PubMed
    Score: 0.011
  15. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163.
    View in: PubMed
    Score: 0.011
  16. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):370-377.
    View in: PubMed
    Score: 0.011
  17. Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. J Clin Oncol. 2023 06 10; 41(17):3217-3224.
    View in: PubMed
    Score: 0.011
  18. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 06 10; 41(17):3203-3216.
    View in: PubMed
    Score: 0.011
  19. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
    View in: PubMed
    Score: 0.011
  20. The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Lancet. 2022 09 17; 400(10356):885-886.
    View in: PubMed
    Score: 0.010
  21. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.010
  22. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274.
    View in: PubMed
    Score: 0.010
  23. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901.
    View in: PubMed
    Score: 0.010
  24. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
    View in: PubMed
    Score: 0.010
  25. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.
    View in: PubMed
    Score: 0.010
  26. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.010
  27. Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. J Neurosurg. 2002 Jan; 96(1):64-70.
    View in: PubMed
    Score: 0.010
  28. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.010
  29. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
    View in: PubMed
    Score: 0.009
  30. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
    View in: PubMed
    Score: 0.009
  31. Coagulopathy as a Surrogate of Severity of Injury in Penetrating Brain Injury. J Neurotrauma. 2021 Jun 01; 38(13):1821-1826.
    View in: PubMed
    Score: 0.009
  32. The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci. 2001 Jan; 56(1):M36-41.
    View in: PubMed
    Score: 0.009
  33. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
    View in: PubMed
    Score: 0.009
  34. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.009
  35. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.009
  36. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
    View in: PubMed
    Score: 0.009
  37. Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
    View in: PubMed
    Score: 0.009
  38. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
    View in: PubMed
    Score: 0.009
  39. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
    View in: PubMed
    Score: 0.009
  40. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
    View in: PubMed
    Score: 0.009
  41. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.008
  42. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
    View in: PubMed
    Score: 0.008
  43. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
    View in: PubMed
    Score: 0.008
  44. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.008
  45. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.008
  46. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.008
  47. Analytical Differences in Intraoperative Parathyroid Hormone Assays. J Appl Lab Med. 2019 03; 3(5):788-798.
    View in: PubMed
    Score: 0.008
  48. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.008
  49. Recurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled? Control Clin Trials. 1998 Oct; 19(5):430-9.
    View in: PubMed
    Score: 0.008
  50. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.
    View in: PubMed
    Score: 0.008
  51. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.008
  52. Season of birth and cockroach allergen sensitization in children with asthma. J Allergy Clin Immunol. 1998 Apr; 101(4 Pt 1):566-8.
    View in: PubMed
    Score: 0.008
  53. Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Ann Allergy Asthma Immunol. 1998 Apr; 80(4):303-8.
    View in: PubMed
    Score: 0.008
  54. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
    View in: PubMed
    Score: 0.008
  55. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.008
  56. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.
    View in: PubMed
    Score: 0.008
  57. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.007
  58. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
    View in: PubMed
    Score: 0.007
  59. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.007
  60. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.
    View in: PubMed
    Score: 0.007
  61. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.006
  62. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.006
  63. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
    View in: PubMed
    Score: 0.006
  64. Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015 Dec 15; 61(12):1815-24.
    View in: PubMed
    Score: 0.006
  65. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.006
  66. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.006
  67. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.006
  68. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.
    View in: PubMed
    Score: 0.006
  69. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.006
  70. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.006
  71. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 2014; 9(7):e100586.
    View in: PubMed
    Score: 0.006
  72. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.006
  73. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.006
  74. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. J Clin Pharmacol. 2014 Jun; 54(6):682-7.
    View in: PubMed
    Score: 0.006
  75. Early removal of urethral catheter with suprapubic tube drainage versus urethral catheter drainage alone after robot-assisted laparoscopic radical prostatectomy. J Urol. 2014 Jul; 192(1):89-95.
    View in: PubMed
    Score: 0.006
  76. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.006
  77. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.006
  78. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.005
  79. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.
    View in: PubMed
    Score: 0.005
  80. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
    View in: PubMed
    Score: 0.005
  81. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
    View in: PubMed
    Score: 0.005
  82. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012 Jun; 54(11):1595-605.
    View in: PubMed
    Score: 0.005
  83. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.005
  84. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.005
  85. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.005
  86. Increased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: a prospective cohort study. Am J Med. 1991 Sep; 91(3):247-54.
    View in: PubMed
    Score: 0.005
  87. Efficacy of daily routine chest radiographs in intubated, mechanically ventilated patients. Crit Care Med. 1991 May; 19(5):689-93.
    View in: PubMed
    Score: 0.005
  88. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
    View in: PubMed
    Score: 0.005
  89. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.005
  90. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.005
  91. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
    View in: PubMed
    Score: 0.004
  92. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.004
  93. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
    View in: PubMed
    Score: 0.004
  94. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.
    View in: PubMed
    Score: 0.004
  95. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
    View in: PubMed
    Score: 0.004
  96. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.004
  97. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.004
  98. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.004
  99. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.004
  100. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.004
  101. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.004
  102. Reproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images. J Clin Densitom. 2008 Apr-Jun; 11(2):211-20.
    View in: PubMed
    Score: 0.004
  103. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum. 2007 Jun 15; 57(5):845-50.
    View in: PubMed
    Score: 0.004
  104. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
    View in: PubMed
    Score: 0.004
  105. Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14.
    View in: PubMed
    Score: 0.004
  106. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006 Aug; 118(2):e379-90.
    View in: PubMed
    Score: 0.003
  107. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
    View in: PubMed
    Score: 0.003
  108. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation. 1986 Apr; 73(4):740-8.
    View in: PubMed
    Score: 0.003
  109. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.003
  110. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.003
  111. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46.
    View in: PubMed
    Score: 0.003
  112. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.003
  113. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14198-203.
    View in: PubMed
    Score: 0.003
  114. Fetal loss associated with excess thyroid hormone exposure. JAMA. 2004 Aug 11; 292(6):691-5.
    View in: PubMed
    Score: 0.003
  115. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.
    View in: PubMed
    Score: 0.003
  116. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004 Jul 06; 141(1):23-7.
    View in: PubMed
    Score: 0.003
  117. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
    View in: PubMed
    Score: 0.003
  118. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9.
    View in: PubMed
    Score: 0.003
  119. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.003
  120. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.003
  121. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
    View in: PubMed
    Score: 0.003
  122. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003 Sep; 238(3):433-41; discussion 442-5.
    View in: PubMed
    Score: 0.003
  123. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.003
  124. Predictors of emergency medical services utilization by elders. Acad Emerg Med. 2003 Jan; 10(1):52-8.
    View in: PubMed
    Score: 0.003
  125. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.003
  126. Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice. J Perinatol. 2002 Jul-Aug; 22(5):341-7.
    View in: PubMed
    Score: 0.003
  127. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002 Jan; 300(1):118-23.
    View in: PubMed
    Score: 0.002
  128. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
    View in: PubMed
    Score: 0.002
  129. HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod. 2001 Dec; 7(12):1167-72.
    View in: PubMed
    Score: 0.002
  130. Factors associated with older patients' satisfaction with care in an inner-city emergency department. Ann Emerg Med. 2001 Aug; 38(2):140-5.
    View in: PubMed
    Score: 0.002
  131. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001 Apr 01; 61(7):2833-7.
    View in: PubMed
    Score: 0.002
  132. Early revisit, hospitalization, or death among older persons discharged from the ED. Am J Emerg Med. 2001 Mar; 19(2):125-9.
    View in: PubMed
    Score: 0.002
  133. A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag. Sleep. 2000 Nov 01; 23(7):915-27.
    View in: PubMed
    Score: 0.002
  134. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000 Apr; 67(4):398-404.
    View in: PubMed
    Score: 0.002
  135. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000 Jan 19; 283(3):367-72.
    View in: PubMed
    Score: 0.002
  136. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999 Dec; 6(12):1232-42.
    View in: PubMed
    Score: 0.002
  137. Older patients' health-related quality of life around an episode of emergency illness. Ann Emerg Med. 1999 Nov; 34(5):595-603.
    View in: PubMed
    Score: 0.002
  138. Safety of peripheral intravenous catheters in children. Infect Control Hosp Epidemiol. 1999 Nov; 20(11):736-40.
    View in: PubMed
    Score: 0.002
  139. The effect of alcohol abuse on the health status of older adults seen in the emergency department. Am J Drug Alcohol Abuse. 1999 Aug; 25(3):529-42.
    View in: PubMed
    Score: 0.002
  140. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet. 1999 Jul 31; 354(9176):365-9.
    View in: PubMed
    Score: 0.002
  141. Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol. 1998 Nov; 40(2):147-57.
    View in: PubMed
    Score: 0.002
  142. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998 May; 114(5):902-11.
    View in: PubMed
    Score: 0.002
  143. Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther. 1998 Mar; 63(3):379-83.
    View in: PubMed
    Score: 0.002
  144. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997 May; 49(5):697-702.
    View in: PubMed
    Score: 0.002
  145. Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol. 1997 Jan; 157(1):90-4.
    View in: PubMed
    Score: 0.002
  146. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep. 1997 Jan-Feb; 112(1):44-51.
    View in: PubMed
    Score: 0.002
  147. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994 Mar 27; 57(6):954-8.
    View in: PubMed
    Score: 0.001
  148. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 1994 Jan; 93(1):114-8.
    View in: PubMed
    Score: 0.001
  149. Autoantibodies and pregnancy history in a healthy population. Am J Obstet Gynecol. 1993 Jul; 169(1):143-7.
    View in: PubMed
    Score: 0.001
  150. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.
    View in: PubMed
    Score: 0.001
  151. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.
    View in: PubMed
    Score: 0.001
  152. Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology. 1992 Jul; 184(1):271-4.
    View in: PubMed
    Score: 0.001
  153. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 1992 Jun; 102(6):1957-61.
    View in: PubMed
    Score: 0.001
  154. Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. JAMA. 1990 Oct 10; 264(14):1824-31.
    View in: PubMed
    Score: 0.001
  155. Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutat Res. 1989 Apr; 216(2):119-26.
    View in: PubMed
    Score: 0.001
  156. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.
    View in: PubMed
    Score: 0.001
  157. Calculation of the systemic delivery rate of insulin in normal man. J Clin Endocrinol Metab. 1986 Jul; 63(1):113-8.
    View in: PubMed
    Score: 0.001
  158. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986 Apr; 35(4):379-86.
    View in: PubMed
    Score: 0.001
  159. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.
    View in: PubMed
    Score: 0.001
  160. Measurements on the internal structure of freeze-fractured cardiac plasma membrane. Am J Physiol. 1985 Mar; 248(3 Pt 2):H297-304.
    View in: PubMed
    Score: 0.001
  161. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest. 1984 Nov; 74(5):1821-9.
    View in: PubMed
    Score: 0.001
  162. Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis. Arch Phys Med Rehabil. 1984 Oct; 65(10):573-8.
    View in: PubMed
    Score: 0.001
  163. P-face particle density of freeze-fractured vertebrate cardiac plasma membrane. Am J Physiol. 1983 Dec; 245(6):H992-7.
    View in: PubMed
    Score: 0.001
  164. A statistical analysis of the loss of muscle strength in Duchenne's muscular dystrophy. Res Commun Chem Pathol Pharmacol. 1982 Jul; 37(1):123-38.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.